The Rogosin Institute has been involved in clinical research for over 40 years and is a pioneer in the treatment of Chronic Renal Insufficiency, End Stage Renal Disease, Transplantation, Polycystic Kidney Disease, Sepsis and Lipid (cholesterol) Disorders, Cancer and Diabetes.
The Institute conducts Phase I, II, III, and IV studies in the therapeutic areas of kidney disease, hemodialysis, peritoneal dialysis, transplantation, hypertension, lipids (cholesterol), polycystic kidney disease and coronary artery disease (secondary to cholesterol and lipid disorders.).
The Institute has been involved as a clinical research site in the developmental process of many commercially available medications for the treatment of cholesterol and renal disorders. The Rogosin Institute has worked and/or is currently working with over twenty pharmaceutical companies and over ten contract research organizations.
In addition to involvement in the clinical drug trials, RI was directly involved in the development of LDL-apheresis, an extracoporeal treatment for patients with severe hypercholesterolemia. The treatment device, Liposorber LA-15, is now available throughout the US and Europe.
The Institute also developed a lipid emulsion, still in the investigational stage, which may be a potential treatment/prevention for endotoxemia. The Institute was responsible for the Phase I, first time in man studies using this emulsion.